基于串联质量标签(TMT)技术筛选差异表达蛋白以区分胸腺瘤(B1和B3)与胸腺囊肿。
Screening differentially expressed proteins to distinguish thymoma (B1 and B3) from thymic cysts based on tandem mass tag (TMT) technology.
发表日期:2024 Oct 21
作者:
Jingwei Shi, Rusong Yang, Xin Chen, Yan Wang, Ye Shi, Yongsheng Wang, Zhengcheng Liu
来源:
Genes & Diseases
摘要:
胸腺囊肿的治疗方法仍然存在争议。识别胸腺囊肿和胸腺瘤(THYM)的预测生物标志物至关重要。在这项研究中,纳入了诊断为胸腺囊肿(MTC,n = 6)和胸腺瘤(B1,n = 6;B3,n = 6)的患者。对优质蛋白进行TMT标记和UPLC-MS,并鉴定差异表达蛋白(DEP)。基因本体论 (GO)、京都基因和基因组百科全书 (KEGG) 以及蛋白质-蛋白质交互网络分析应用于 DEP。通过 GEPIA 32 证实了一些关键差异表达基因 (DEG)。利用阿拉巴马大学伯明翰分校癌症数据分析门户 (UALCAN) 确定了与预后显着相关的关键 DEG 的泛癌表达水平。最终,在 B1 与 MTC 比较中确定了 49 个 DEP(17 个上调,32 个下调),在 B3 与 MTC 比较中确定了 27 个 DEP(8 个上调,19 个下调),在 B3 与 B1 比较中确定了 38 个(9 个上调,19 个下调)。 29 下调)。 IL13RA1(下调)、半乳糖凝集素 3 结合蛋白(LGALS3BP)(上调)、PRCSH(下调)、C3(下调)、MXRA5(下调)、TNN(下调)、CFHR1(下调)、SUN3(下调)在B1 对 NZ 和 B3 对 NZ。 GEPIA 证实 LGALS3BP 在胸腺瘤患者中显着上调。总之,LGALS3BP 可能是识别胸腺瘤和胸腺囊肿的重要生物标志物。© 2024。作者。
The therapeutic approach to thymic cysts remains a subject of controversy. Predicted biomarkers for identifying thymic cysts and thymoma (THYM) are crucial. In this research, patients diagnosed with thymic cysts (MTC, n = 6) and thymoma (B1, n = 6; B3, n = 6) were enrolled. Proteins of superior quality were subjected to TMT labeling and UPLC-MS, and differentially expressed proteins (DEPs) were identified. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interactive network analyses were applied to the DEPs. Some key differentially expressed genes(DEGs) were corroborated through GEPIA 32. The pan-cancer expression levels of key DEGs remarkably linked with prognosis were determined utilizing The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN). Eventually, 49 DEPs were identified in the B1 vs. MTC comparison (17 upregulated and 32 downregulated), 27 in the B3 vs. MTC comparison (8 upregulated and 19 downregulated), and 38 in the B3 vs. B1 comparison (9 upregulated and 29 downregulated). IL13RA1 (down), galectin-3 binding protein (LGALS3BP)(up), PRCSH (down), C3 (down), MXRA5 (down), TNN (down), CFHR1 (down), SUN3 (down) were jointly altered in both B1 vs. NZ and B3 vs. NZ. GEPIA validated that LGALS3BP was significantly upregulated in thymoma patients. In conclusion, LGALS3BP might be an essential biomarker to identify thymoma from the thymic cyst.© 2024. The Author(s).